41 research outputs found
Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer
Context: Human securin pituitary tumor-transforming gene (hPTTG) is overexpressed in a variety of primary neoplasias, including differentiated thyroid cancer (DTC). Objective: The objective of this study was to examine the immunohistochemical expression of hPTTG in DTC and its association with known prognostic factors. Design: hPTTG expression was analyzed by immunostaining on paraffin-embedded tissues. Clinical data were used to determine any associations between the expression of hPTTG and prognostic variables of DTC. A median follow-up of 43 months allowed us to analyze the persistence of disease and the response to radioiodine therapy. Setting: The study was conducted at a tertiary university hospital. Patients: Ninety-five patients undergoing surgical resection for DTC (n = 60) or benign nodular thyroid disease (n = 35) were studied. Main Outcome Measure: The main outcome measure was the association between hPTTG expression and prognostic factors in DTC. Results: Among DTC cases, 21 (35%) had low and 39 (65%) had high hPTTG immunostaining. Adjacent nonneoplastic thyroid tissue was largely unstained. Among benign nodular thyroid disease cases, immunostaining was detected focally in eight (22.8%). A significant association was found between hPTTG expression and the presence of nodal (P < 0.01) or distant metastases (P < 0.05). A significant association with TNM was also found, because 83.3% of advanced TNM stages showed elevated hPTTG (P < 0.05). The association between hPTTG overexpression and decreased radioiodine uptake during follow-up was also significant (P < 0.05). The expression levels of hPTTG were confirmed as an independent prognostic factor for persistent disease (relative risk, 3.0; 95% confidence interval, 1.1-8.7; P < 0.05). Conclusions: Immunohistochemical analysis of hPTTG is of potential value in the determination of tumor aggressiveness in DTC.Peer Reviewe
Downregulation of protein tyrosine phosphatase PTPL1 alters cell cycle and upregulates invasion-related genes in prostate cancer cells
The final publication is available at link.springer.comPTPL1, a non-receptor type protein tyrosine phosphatase, has been involved in the regulation of apoptosis and invasiveness of various tumour cell types, but its role in prostate cancer remained to be investigated. We report here that downregulation of PTPL1 by small interfering RNA in PC3 cells decreases cell proliferation and concomitantly reduces the expression of cell cycle-related proteins such as cyclins E and B1, PCNA, PTTG1 and phospho-histone H3. PTPL1 downregulation also increases the invasion ability of PC3 cells through Matrigel coated membranes. cDNA array of PTPL1-silenced PC3 cells versus control cells showed an upregulation of invasion-related genes such as uPA, uPAR, tPA, PAI-1, integrin α6 and osteopontin. This increased expression was also confirmed in PTPL1-silenced DU145 prostate cancer cells by quantitative real time PCR and western blot. These findings suggest that PTPL1 is an important mediator of central cellular processes such as proliferation and invasion. © 2012 Springer Science+Business Media B.V.This work was supported by Grants from the Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III, Spain (FIS PI10/02026 and SAF2008-05046-C02-02), ISCIIIRETIC-RD06/0020-FEDER, Consejería de Salud (PI-2009-0589, AI-2010-003 to M.A.J.), and Consejería de Innovación, Ciencia y Empresa (CTS-6243), Junta de Andalucía (06/189, PI-2009-0589, and AI-2010-003 to M. A. J.). C. C. was supported by a pre-doctoral Grant from the Spanish Ministerio de Educación (F.P.I.: BES200612419) co-financiated by Fondo Social Europeo. C. S. was supported by a contract from Instituto de Salud Carlos III/FIS and Fundación Progreso y Salud, Consejería de Salud, Junta de Andalucía, Miguel Servet Program.Peer Reviewe
E-cadherin expression is associated with somatostatin analogue response in acromegaly
Acromegaly is a rare disease resulting from hypersecretion of growth hormone (GH)
and insulin‐like growth factor 1 (IGF1) typically caused by pituitary adenomas, which
is associated with increased mortality and morbidity. Somatostatin analogues (SSAs)
represent the primary medical therapy for acromegaly and are currently used as
first‐line treatment or as second‐line therapy after unsuccessful pituitary surgery.
However, a considerable proportion of patients do not adequately respond to SSAs
treatment, and therefore, there is an urgent need to identify biomarkers predictors
of response to SSAs. The aim of this study was to examine E‐cadherin expression
by immunohistochemistry in fifty‐five GH‐producing pituitary tumours and determine
the potential association with response to SSAs as well as other clinical and
histopathological features. Acromegaly patients with tumours expressing low E‐cadherin
levels exhibit a worse response to SSAs. E‐cadherin levels are associated with
GH‐producing tumour histological subtypes. Our results indicate that the immunohistochemical
detection of E‐cadherin might be useful in categorizing acromegaly
patients based on the response to SSAs.ISCIII‐Subdirección General de Evaluación y Fomento de la Investigación PI13/02043 PI16/00175FEDER PI13/02043 PI16/00175Junta de Andalucía A‐0023‐2015 A‐0003‐2016 CTS‐1406 BIO‐0139Andalusian Ministry of Health C‐0015‐2014CIBERobn PI13/ 02043 PI16/0017
Methylation alterations are not a major cause of PTTG1 missregulation
Background: On its physiological cellular context, PTTG1 controls sister chromatid segregation
during mitosis. Within its crosstalk to the cellular arrest machinery, relies a checkpoint of integrity
for which gained the over name of securin. PTTG1 was found to promote malignant transformation
in 3T3 fibroblasts, and further found to be overexpressed in different tumor types. More recently,
PTTG1 has been also related to different processes such as DNA repair and found to trans-activate
different cellular pathways involving c-myc, bax or p53, among others. PTTG1 over-expression has
been correlated to a worse prognosis in thyroid, lung, colorectal cancer patients, and it can not be
excluded that this effect may also occur in other tumor types. Despite the clinical relevance and
the increasing molecular characterization of PTTG1, the reason for its up-regulation remains
unclear.
Method: We analysed PTTG1 differential expression in PC-3, DU-145 and LNCaP tumor cell
lines, cultured in the presence of the methyl-transferase inhibitor 5-Aza-2'-deoxycytidine. We also
tested whether the CpG island mapping PTTG1 proximal promoter evidenced a differential
methylation pattern in differentiated thyroid cancer biopsies concordant to their PTTG1
immunohistochemistry status. Finally, we performed whole-genome LOH studies using Affymetix
50 K microarray technology and FRET analysis to search for allelic imbalances comprising the
PTTG1 locus.
Conclusion: Our data suggest that neither methylation alterations nor LOH are involved in
PTTG1 over-expression. These data, together with those previously reported, point towards a
post-transcriptional level of missregulation associated to PTTG1 over-expression.This project was funded by The Fundación de Investigación Biomédica Mutua Madrileña Automovilista. Neocodex have been partially funded by the Ministerio de Educación y Ciencia of Spain (FIT-010000-2004-69, PTQ04-1-0006, PTQ2003-0549, PTQ2003-0546 and PTQ2003-0783). MAJ was also supported by SAF2005- 07713-C03-03 and CS by FIS 06/757
Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer
FBXW7 is a component of SCF (complex of SKP1, CUL1 and F-box-protein)-type ubiquitin ligases that targets several oncoproteins for ubiquitination and degradation by the proteasome. FBXW7 regulates cellular apoptosis by targeting MCL1 for ubiquitination. Recently, we identified PLK1 as a new substrate of FBXW7 modulating the intra-S-phase DNA-damage checkpoint. Taxanes are frequently used in breast cancer treatments, but the acquisition of resistance makes these treatments ineffective. We investigated the role of FBXW7 and their substrates MCL1 and PLK1 in regulating the apoptotic response to paclitaxel treatment in breast cancer cells and their expression in breast cancer tissues. Paclitaxel-sensitive MDA-MB-468 and a paclitaxel-resistant MDA-MB-468R subclone were used to study the role of FBXW7 and substrates in paclitaxel-induced apoptosis. Forced expression of FBXW7 or downregulation of MCL1 or PLK1 restored sensitivity to paclitaxel in MDA-MB-468R cells. By contrary, FBXW7-silenced MDA-MB-468 cells became resistant to paclitaxel. The expression of FBXW7 and substrates were studied in 296 invasive carcinomas by immunohistochemistry and disease-free survival was analyzed in a subset of patients treated with paclitaxel. In breast cancer tissues, loss of FBXW7 correlated with adverse prognosis markers and loss of FBXW7 and MCL1 or PLK1 accumulation were associated with diminished disease-free survival in paclitaxel-treated patients. We conclude that FBXW7 regulates the response to paclitaxel by targeting MCL1 and PLK1 in breast cancer cells and thus targeting these substrates may be a valuable adjunct for paclitaxel treatment. Also, FBXW7, MCL1 and PLK1 may be relevant predictive markers of tumor progression and response to paclitaxel treatment.España, Ministerio de Economía y Competitividad SAF2014- 53799-C2-1/2-REspaña, Consejería de Salud AI-0025-2015España, Consejería de Innovación Ciencia y Empresa P10- CTS-624
A Silent Corticotroph Pituitary Carcinoma: Lessons From an Exceptional Case Report
Nowadays, neither imaging nor pathology evaluation can accurately predict the aggressiveness or treatment resistance of pituitary tumors at diagnosis. However, histological examination can provide useful information that might alert clinicians about the nature of pituitary tumors. Here, we describe our experience with a silent corticothoph tumor with unusual pathology, aggressive local invasion and metastatic dissemination during follow-up. We present a 61-year-old man with third cranial nerve palsy at presentation due to invasive pituitary tumor. Subtotal surgical approach was performed with a diagnosis of silent corticotroph tumor but with unusual histological features (nuclear atypia, frequent multinucleation and mitotic figures, and Ki-67 labeling index up to 70%). After a rapid regrowth, a second surgical intervention achieved successful debulking. Temozolomide treatment followed by stereotactic fractionated radiotherapy associated with temozolomide successfully managed the primary tumor. However, sacral metastasis showed up 6 months after radiotherapy treatment. Due to aggressive distant behavior, a carboplatine-etoposide scheme was decided but the patient died of urinary sepsis 31 months after the first symptoms. Our case report shows how the presentation of a pituitary tumor with aggressive features should raise a suspicion of malignancy and the need of follow up by multidisciplinary team with experience in its management. Metastases may occur even if the primary tumor is well controlled.This work was supported by grants from the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación co-funded with Fondos FEDER (PI16/00175 to AS-M and DC) and the Sistema Andaluz de Salud (A-0003-2016 and A-0006-2017 to AS-M, C-0015-2014 and RC-0006-2018 to DC)
In1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases their aggressive features
Pituitary adenomas comprise a heterogeneous subset of pathologies causing serious comorbidities, which
would benefit from identification of novel, common molecular/cellular biomarkers and therapeutic targets.
The ghrelin system has been linked to development of certain endocrine-related cancers. Systematic analysis
of the presence and functional implications of some components of the ghrelin system, including native
ghrelin, receptors and the recently discovered splicing variant In1-ghrelin, in human normal pituitaries (n
5 11) and pituitary adenomas (n 5 169) revealed that expression pattern of ghrelin system suffers a clear
alteration in pituitary adenomasas comparedwith normal pituitary, where In1-ghrelin is markedly
overexpressed. Interestingly, in cultured pituitary adenoma cells In1-ghrelin treatment (acylated peptides at
100 nM; 24–72 h) increasedGHandACTHsecretion, Ca21 and ERK1/2 signaling and cell viability, whereas
In1-ghrelin silencing (using a specific siRNA; 100 nM) reduced cell viability. These results indicate that an
alteration of the ghrelin system, specially its In1-ghrelin variant, could contribute to pathogenesis of
different pituitary adenomas types, and suggest that this variant and its related ghrelin system could provide
new tools to identify novel, more general diagnostic, prognostic and potential therapeutic targets in
pituitary tumors
A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
[Purpose] Somatostatin analogues (SSA) are efficacious and safe treatments for a variety of neuroendocrine tumors, especially pituitary neuroendocrine tumors (PitNET). Their therapeutic effects are mainly mediated by somatostatin receptors SST2 and SST5. Most SSAs, such as octreotide/lanreotide/pasireotide, are either nonselective or activate mainly SST2. However, nonfunctioning pituitary tumors (NFPTs), the most common PitNET type, mainly express SST3 and finding peptides that activate this particular somatostatin receptor has been very challenging. Therefore, the main objective of this study was to identify SST3-agonists and characterize their effects on experimental NFPT models.[Experimental Design] Binding to SSTs and cAMP level determinations were used to screen a peptide library and identify SST3-agonists. Key functional parameters (cell viability/caspase activity/chromogranin-A secretion/mRNA expression/intracellular signaling pathways) were assessed on NFPT primary cell cultures in response to SST3-agonists. Tumor growth was assessed in a preclinical PitNET mouse model treated with a SST3-agonist.
[Results] We successfully identified the first SST3-agonist peptides. SST3-agonists lowered cell viability and chromogranin-A secretion, increased apoptosis in vitro, and reduced tumor growth in a preclinical PitNET model. As expected, inhibition of cell viability in response to SST3-agonists defined two NFPT populations: responsive and unresponsive, wherein responsive NFPTs expressed more SST3 than unresponsive NFPTs and exhibited a profound reduction of MAPK, PI3K-AKT/mTOR, and JAK/STAT signaling pathways upon SST3-agonist treatments. Concurrently, SSTR3 silencing increased cell viability in a subset of NFPTs.
[Conclusions] This study demonstrates that SST3-agonists activate signaling mechanisms that reduce NFPT cell viability and inhibit pituitary tumor growth in experimental models that expresses SST3, suggesting that targeting this receptor could be an efficacious treatment for NFPTs.This work has been funded by the following grants: Junta de Andalucía [CTS-1406 (R.M. Luque), BIO-0139 (J.P. Castaño)]; Ministerio de Ciencia, Innovación y Universidades [BFU2016-80360-R (J.P. Castaño)] and Instituto de Salud Carlos III, co-funded by European Union [ERDF/ESF, “Investing in your future”: PI16/00264 (R.M. Luque), CP15/00156 (M.D. Gahete) and CIBERobn]. CIBER is an initiative of Instituto de Salud Carlos III
Differential expression of THOC1 and ALY mRNP biogenesis/export factors in human cancers
<p>Abstract</p> <p>Background</p> <p>One key step in gene expression is the biogenesis of mRNA ribonucleoparticle complexes (mRNPs). Formation of the mRNP requires the participation of a number of conserved factors such as the THO complex. THO interacts physically and functionally with the Sub2/UAP56 RNA-dependent ATPase, and the Yra1/REF1/ALY RNA-binding protein linking transcription, mRNA export and genome integrity. Given the link between genome instability and cancer, we have performed a comparative analysis of the expression patterns of THOC1, a THO complex subunit, and ALY in tumor samples.</p> <p>Methods</p> <p>The mRNA levels were measured by quantitative real-time PCR and hybridization of a tumor tissue cDNA array; and the protein levels and distribution by immunostaining of a custom tissue array containing a set of paraffin-embedded samples of different tumor and normal tissues followed by statistical analysis.</p> <p>Results</p> <p>We show that the expression of two mRNP factors, THOC1 and ALY are altered in several tumor tissues. THOC1 mRNA and protein levels are up-regulated in ovarian and lung tumors and down-regulated in those of testis and skin, whereas ALY is altered in a wide variety of tumors. In contrast to THOC1, ALY protein is highly detected in normal proliferative cells, but poorly in high-grade cancers.</p> <p>Conclusions</p> <p>These results suggest a differential connection between tumorogenesis and the expression levels of human THO and ALY. This study opens the possibility of defining mRNP biogenesis factors as putative players in cell proliferation that could contribute to tumor development.</p